Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
AstraZeneca
McKesson
McKinsey
Moodys

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for Anacor Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2018)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Anacor Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2018)

Docket   Start Trial Date Filed 2018-10-17
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties ANACOR PHARMACEUTICALS, INC.; ENCUBE ETHICALS PVT. LTD.; FLATWING PHARMACEUTICALS, LLC; GLASSHOUSE PHARMACEUTICALS LIMITED CANADA; LUPIN LIMITED; LUPIN PHARMACEUTICALS, INC.
Patents 9,566,289; 9,566,290; 9,572,823
Attorneys Andrea L. Cheek; Aryeh N. Feinstein; Carol M. Pitzel Cruz; David A. Gerasimow; David M. Fry; Don J. Mizerk; Frederick L. Cottrell , III; Gary J. Speier; Jack B. Blumenfeld; John C. Phillips , Jr.; Karen Elizabeth Keller; Katharine Lester Mowery; Kelly E. Farnan; Marc R. Wezowski; Megan C. Haney; Megan E. Hingtgen; Megan Elizabeth Dellinger; Renee Marie Mosley; Samuel T. Lockner; William R. Zimmerman
Firms Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Anacor Pharmaceuticals, Inc. v. Lupin Limited
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Anacor Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 of U.S. Patent No. 9,459,938 (“the ’938 patent”); U.S. Patent No. 9,566,289 (“the ’289 patent”); U.S. …. Patent No. 9,566,290 (“the ’290 patent”); and U.S. Patent No. 9,572,823 (“the ’823 patent”). These…the ’938 patent, the ’290 patent, the ’823 patent, or claims 1–5 or 7–15 of the ’289 patent. …the ’938 patent, the ’290 patent, the ’823 patent, or claims 1–5 or 7–15 of the ’289 patent. …the ’289 patent; claims 2, 5–6, 8, and 11–12 of the ’290 patent; and claim 2 of the ’823 patent. External link to document
0000-00-00 4 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,459,938 B2; 9,566,289 B2; 9,566,290… 17 October 2018 1:18-cv-01606 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Express Scripts
McKinsey
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.